Fujisawa Pharmaceutical Company, Ltd.

Other

Astellas Pharma Gmbh

Pearl Kogyo Co., Ltd.

Bbk Bio Corporation

Shintaro Nishimura

Nobuyoshi Yasuda

Takao Takaya

Atsushi Akahane

Zenzaburo Tozuka

Hiromichi Itani

Hiroyuki Arakawa

Kazuo Sakane

Eiichi Nakamura

Susumu Satoh

Yoshihiro Murakami

Susumu Sato

Masahiko Morita

Mayako Yamazaki

Sousuke Miyoshi

Kieran P M Durkin

Hideki Yorimitsu

Satoshi Minoshima

Ichiro Matsunari

Akiko Ohkubo

Hiroshi Myogan

Noriyuki Morikawa

Kazuyoshi Yajima

Yasuhiro Ogawa

Masao Fukagawa

Yasuhiro Kita

Jyunko Zenkou

Kieran P Durkin

Takao Yamazaki

This invention relates to novelO-labeled monosaccharide useful for positron emission tomography (PET) and producing method thereof.

[object Object]

A method of highly efficiently transferring various selected molecules into various cells and a method of fusing cells. Cells and/or selected molecules such as polynucleotide are treated with cold gas plasma to thereby transfer the selected molecules located around cells into the cells, or cells are fused by treating the cells with cold gas plasma. Moreover, an apparatus for transferring selected molecules or fusing cells having a cold gas plasma generation unit for transferring selected molecules into cells is provided.

Method of transferring a selected molecule into a cell

The present invention identified OVARC1000473 (SEQ ID NO: 1) and NT2RM1000377 (SEQ ID NO: 3) as clones showing suppression of CREB activation by forskolin, and provides evaluation methods using these genes, and/or proteins encoded by these genes. Furthermore, these proteins were found to enhance cell damage. Compounds that can be screened based on the evaluation methods of this invention are useful as agents for inhibiting the CREB dephosphorylation reaction, agents for suppressing enhancement of cell damage, and preventive and therapeutic agents for memory disorders and/or neurodegenerative disorders.

Methods of evaluating phosphatase inhibitors

Primaiy supernatant liquid collector allows blood A to separate into a primary supernatant liquid B and red blood cells by leaving the blood A stationary for a prescribed period of time, and then it discharges the primary supernatant liquid B and physiological saline W in the same amount into a first treatment container and a first balance container , respectively. Centrifuge centrifuges the above primary supernatant liquid B using the first balance container as a balance weight, and a secondary supernatant liquid in the first treatment container is transferred to a second treatment container by take-out device and at the same time the physiological saline W in the same amount as the transferred secondary supernatant liquid is transferred from the first balance container to a second balance container

Supernatant liquid collector with balance weight forming function and centrifugal apparatus using the same

Pyrazolopyridine adenosine antagonists

A water-soluble antibiotic composition which comprises crystals of a cephem compound of the following formula: ##STR1## wherein R.sup.1 is a residue of an aliphatic hydrocarbon which may have suitable substituent(s), and

Water-soluble antibiotic composition and water-soluble salts of cephem

A compound of the formula: ##STR1## wherein R.sup.1 is lower alkyl, lower alkanoyl, aryl, ar(lower)alkyl or a heterocyclic group, each of which may have suitable substituent(s),

Cephem compounds and processes for preparation thereof

Cephem compounds

Growing community of inventors

Osaka, Japan

Shintaro Nishimura